EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Safety, Dosimetry, and Feasibility of [ 68 Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer

Liza Lindenberg, Thomas A Hope, Frank I Lin, Steven P Rowe, Darko Pucar, Noella Gilbert, Daniela Chicco, Beilei He, Benedikt Feuerecker, Elena Castaldi, Lilja B Solnes

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268318 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Liza Lindenberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Safety. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is highly expressed in most prostate cancers (PCs). PET and CT imaging studies using 68Ga-labeled PSMA ligands demonstrated the specific localization of 68Ga in PC lesions and distant metastatic lesions. [68Ga]Ga-PSMA-R2 (68Ga-PSMA-R2) is a PSMA-targeted PET/CT radiotracer with potential diagnostic applications.

Methods

PROfind (NCT03490032) was a phase 1/2, open-label, multicenter study of administration of 3 MBq/kg of 68Ga-PSMA-R2 (from >150 to ≤250 MBq) in patients with biochemical recurrence (BCR) or metastatic PC (mPC). Participants underwent baseline conventional imaging (CT/MRI or bone scan) and PET/CT. Whole-body PET/CT imaging sequences were obtained between 20 min and 4 h after injection. Primary endpoints were safety and tolerability; secondary endpoints included biodistribution, potential lesion identification, pharmacokinetics, and dosimetry. Potential lesions were identified by 2 masked expert panels; a third panel evaluated the identified lesions.

Results

Six patients with BCR were enrolled into phase 1, and 24 patients with BCR or mPC (n = 12 each) into phase 2. Thirteen treatment-emergent adverse events were reported, including 1 serious adverse event (ileus), unrelated to drug administration. All adverse events were mild or moderate and deemed not related to 68Ga-PSMA-R2. Peak blood concentration of 68Ga-PSMA-R2 was typically observed approximately 5 min after injection, steadily decreasing over 6 h. Mean absorbed radiation dose was highest in the urinary bladder wall (0.120 mGy/MBq) and kidney (0.061 mGy/MBq). No other organ mean absorbed radiation dose exceeded 0.020 mGy/MBq. Mean absorbed radiation doses in the salivary and lacrimal glands were 0.016 and 0.008 mGy/MBq, respectively. Mean total body absorbed radiation dose was 0.014 mGy/MBq. Mean effective total body dose was 0.015 mSv/MBq (range, 0.012-0.018 mSv/MBq). 68Ga-PSMA-R2 PET/CT detected 85 lesions in 22 participants at 1 h after injection and 103 lesions in 22 participants at 2 h after injection. Conventional imaging detected 49 lesions in 8 participants with mPC but none in participants with BCR.

Conclusion

68Ga-PSMA-R2 was well tolerated, with no drug-related treatment-emergent adverse events. Safety and preliminary imaging performance data support further development of 68Ga-PSMA-R2 as a diagnostic agent in patients with PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsSafetyHumansMaleGallium RadioisotopesPositron Emission Tomography Computed TomographyAgedMiddle AgedFeasibility StudiesRadiometryNeoplasm MetastasisGallium IsotopesRecurrenceTissue DistributionAged, 80 and over

Stichwörter der Autor:innen

68Ga-PSMA-R2PETPSMAdosimetryprostate cancer

Substanzen

Gallium RadioisotopesGallium IsotopesGallium-68gallium 68 PSMA-11

Autor:innen und Institutionen

  • Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • University of California, San Francisco, California.
  • Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.
  • Yale University, New Haven, Connecticut.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Advanced Accelerator Applications, a Novartis Company, Turin, Italy.

Förderung

  • NCI NIH HHS

Zitieren

APA

Lindenberg, L., Hope, T. A., Lin, F. I., Rowe, S. P., Pucar, D., Gilbert, N., Chicco, D., He, B., Feuerecker, B., Castaldi, E., & Solnes, L. B. (2025). Safety, Dosimetry, and Feasibility of [ 68 Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268318

Vancouver

Lindenberg L, Hope TA, Lin FI, Rowe SP, Pucar D, Gilbert N, et al. Safety, Dosimetry, and Feasibility of [ 68 Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268318

BibTeX
@article{Lindenberg2025,
  author = {Lindenberg, Liza and Hope, Thomas A and Lin, Frank I and Rowe, Steven P and Pucar, Darko and Gilbert, Noella and Chicco, Daniela and He, Beilei and Feuerecker, Benedikt and Castaldi, Elena and Solnes, Lilja B},
  title = {Safety, Dosimetry, and Feasibility of [ 68 Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268318}
}
Kostenlos starten →